Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study - Archive ouverte HAL Access content directly
Journal Articles Blood Year : 2010

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

(1) , (1) , (1) , (1) , (1) , (1) , (2) , (1) , (1) , (3) , (1) , (1) , (4) , (1)
1
2
3
4
Philippe Moreau
Arnaud Jaccard
  • Function : Author
  • PersonId : 972533
Bruno Royer
  • Function : Author
Xavier Leleu
  • Function : Author
Gilles Salles
May Alakl
  • Function : Author
Olivier Hermine
  • Function : Author
  • PersonId : 849336
Lucie Planche
  • Function : Author
  • PersonId : 895629

Abstract

New treatment options are required for primary systemic amyloid light chain (AL) amyloidosis. This phase 1/2 dose-escalation study aimed to determine the maximum tolerated dose (MTD) of lenalidomide in combination with melphalan and dexamethasone (M-dex), and assess the efficacy and tolerability of this therapy for patients with de novo AL amyloidosis. Twenty-six patients were enrolled across 4 cohorts: M-dex + lenalidomide 5, 10, 15, and 20 mg once daily on days 1 to 21 in a 28-day cycle. No dose limiting toxicity (DLT) was observed in cohorts 1, 2, and 3. 4. Seven patients in cohort 4, M-dex + lenalidomide 20 mg/day, experienced DLT. MTD was defined as 15 mg of lenalidomide. A complete hematologic response was achieved in 42% at the dose of 15 mg of lenalidomide per day. After a median follow-up of 19 months, estimated 2-year overall survival (OS) and event-free survival (EFS) were 80.8% and 53.8%, respectively. Hematologic and organ responses were both associated with superior EFS rates (P = .0001). A higher EFS was also observed in patients whose free light chains decreased by more than 50% during therapy (P = .019). Lenalidomide 15 mg/d + M-dex is a new effective combination therapy in patients with newly diagnosed AL amyloidosis. This study is registered at www.clinicaltrials.gov as NCT00621400.
Not file

Dates and versions

ensl-00817195 , version 1 (24-04-2013)

Identifiers

  • HAL Id : ensl-00817195 , version 1

Cite

Philippe Moreau, Arnaud Jaccard, Lofti Benboucker, Bruno Royer, Xavier Leleu, et al.. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood, 2010, 116 (23), pp.4777-4782. ⟨ensl-00817195⟩

Collections

ENS-LYON UDL
100 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More